Reports of Biochemistry
and Molecular Biology
Sat, Dec 21, 2024
[Archive]
Volume 13, Issue 1 (Vol.13 No.1 Apr 2024)
rbmb.net 2024, 13(1): 106-113 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Gihad Falh Z, Oied Mohammed Saleh B, Mahjoob AL-Naddawi A. Association of Serum Anti-Mullerian Hormone and Free Testosterone with Different Phenotypes of Polycystic Ovary Syndrome. rbmb.net 2024; 13 (1) :106-113
URL: http://rbmb.net/article-1-1376-en.html
URL: http://rbmb.net/article-1-1376-en.html
Department of biochemistry, College of Medicine, University of Baghdad, Iraq.
Abstract: (524 Views)
Background: Anti-Müllerian hormone (AMH) has lately been connected to polycystic ovary syndrome (PCOS) in a growing body of research, even though hyperandrogenism is one of the primary symptoms of PCOS.
Evaluate the association of serum anti-Müllerian hormone and free testosterone with different phenotypes of polycystic ovary syndrome.
Methods: This is cross-sectional study was carried out at Department of Biochemistry, College of Medicine, University of Baghdad, during the period from November 2023 to March 2024. It included 111 women, 91 of these women, age range (18-40 year) were diagnosed with polycystic ovary syndrome according to 2003 Rotterdam Consensus criteria, and 20 women were apparently healthy women. The PCOS women were sub-grouped into four phenotype groups (A, B, C and D). Investigations included serum measurements of free testosterone and anti-müllerian hormone by using enzyme linked immunosorbent assay (ELISA) technique in all included women.
Result: The results revealed that phenotype A is the predominant one of PCOS, while the B phenotype is the rare one. The mean (±SEM) values of free testosterone levels of phenotypes A, B, and C were significantly higher those of phenotype D and controls (p=0.001). The mean (±SEM) value of serum anti-Mullerian hormone levels was significantly increased in phenotypes A (p=0.04) and D (p=0.01) than C phenotype.
Conclusions: Phenotype A is the predominant one of PCOS phenotypes and is associated with highest serum AMH, free testosterone and obesity. Both free testosterone and AMH are helpful in differentiation of different phenotypes of PCOS.
Evaluate the association of serum anti-Müllerian hormone and free testosterone with different phenotypes of polycystic ovary syndrome.
Methods: This is cross-sectional study was carried out at Department of Biochemistry, College of Medicine, University of Baghdad, during the period from November 2023 to March 2024. It included 111 women, 91 of these women, age range (18-40 year) were diagnosed with polycystic ovary syndrome according to 2003 Rotterdam Consensus criteria, and 20 women were apparently healthy women. The PCOS women were sub-grouped into four phenotype groups (A, B, C and D). Investigations included serum measurements of free testosterone and anti-müllerian hormone by using enzyme linked immunosorbent assay (ELISA) technique in all included women.
Result: The results revealed that phenotype A is the predominant one of PCOS, while the B phenotype is the rare one. The mean (±SEM) values of free testosterone levels of phenotypes A, B, and C were significantly higher those of phenotype D and controls (p=0.001). The mean (±SEM) value of serum anti-Mullerian hormone levels was significantly increased in phenotypes A (p=0.04) and D (p=0.01) than C phenotype.
Conclusions: Phenotype A is the predominant one of PCOS phenotypes and is associated with highest serum AMH, free testosterone and obesity. Both free testosterone and AMH are helpful in differentiation of different phenotypes of PCOS.
Type of Article: Original Article |
Subject:
Biochemistry
Received: 2024/04/21 | Accepted: 2024/08/25 | Published: 2024/10/22
Received: 2024/04/21 | Accepted: 2024/08/25 | Published: 2024/10/22
References
1. Hamdi RA, Abdul-Qahar ZH, Kadhum EJ, Alsaeed FA. Assessment of Serum Vitamin D Levels in Women with Polycystic Ovary Syndrome. J Fac Med Baghdad. 2018;60(2):93-7. [DOI:10.32007/19jfacmedbaghdad36.v60i2.12]
2. Mutashar M, Dr. Manal Kamal Rasheed, Dr. Afraa Mahjoba Al-Naddawi. Association of Neuregulin-4 levels and body mass index with hyperandrogenism in Polycystic Ovary Syndrome patients. J Fac Med Baghdad. 2024;65(4):279-285. [DOI:10.32007/jfacmedbagdad.2140]
3. Hatem A, Saleh BOM, Al-Naddawi A. Association between serum fructose level and insulin resistance in women with polycystic ovary syndrome: The effect of obesity. J Fac Med Baghdad. 2022;64(2):91-5. [DOI:10.32007/jfacmedbagdad.6421926]
4. S Shenta A, Saud K, Al-Shawi A. Assessment the Correlations of Hormones, Lipid Profiles, Oxidative Stress, and Zinc Concentration in Iraqi Women with Polycystic Ovary Syndrome. Rep Biochem Mol Biol. 2020;9(3):270-277. [DOI:10.29252/rbmb.9.3.270] [PMID] []
5. Ibrahim WW, Salah RK, Abbas WM. Serum Prostate Specific Antigen level in Women with Polycystic Ovary Syndrome. J Fac Med Baghdad. 2016;58(2):136-9. [DOI:10.32007/jfacmedbagdad.582224]
6. Ran Y, Yi Q, Li C. The relationship of anti-Mullerian hormone in polycystic ovary syndrome patients with different subgroups. Diabetes, Metab Syndr Obes. 2021;14;1419-1424. [DOI:10.2147/DMSO.S299558] [PMID] []
7. Polak AM, Adamska A, Krentowska A, Łebkowska A, Hryniewicka J, Adamski M, Adamski M, Kowalska I. Body composition, serum concentrations of androgens and insulin resistance in different polycystic ovary syndrome phenotypes. J Clin Med. 2020;9(3):732. [DOI:10.3390/jcm9030732] [PMID] []
8. Abbood AH, Majeed Hameed R, Ghazi Al Safi W. Neuregulin 4 in Polycystic Ovarian Syndrome (PCOS) Phenotypes: A Key Role or Standby. Rep Biochem Mol Biol. 2023;12(3):359-365.
9. Abd Al-Ghanny RJ, Al-Moosawi MMB, Abd BA. Effects of Vitamin D Deficiency in Polycystic Ovarian Syndrome. Iraqi J Sci. 2022;63(10):33-42. [DOI:10.24996/ijs.2022.63.1.4]
10. Carmina E, Azziz R. Diagnosis, phenotype and prevalence of PCOS. Fertil Steril. 2006;86 Suppl 1:S7-8. [DOI:10.1016/j.fertnstert.2006.03.012] [PMID]
11. Broer SL, Broekmans FJ, Laven JS, Fauser BC. Anti-Müllerian hormone: ovarian reserve testing and its potential clinical implications. Hum Reprod Update. 2014;20(5):688-701. [DOI:10.1093/humupd/dmu020] [PMID]
12. Ghasemi Tehrani H, Aasasi K, Mardanian F, Mehrabian F, Movahedi M, Naghshineh E. Evaluation of The Effect of Letrozole in the Ovarian Hyperstimulation Syndrome Prevention in Participants at Risk of Treatment with Ovulation-Stimulating Drugs : A Randomized Controlled Trial. Rep Biochem Mol Biol. 2022 Oct;11(3):386-393. [DOI:10.52547/rbmb.11.3.386] [PMID] []
13. Alawad ZM. Level of follicular fluid vitamin D and embryo quality in a sample of Iraqi women undergoing IVF. J Fac Med Baghdad. 2019;60(4):215-21.
https://doi.org/10.32007/med.1936/jfacmedbagdad.v60i4.7 [DOI:10.32007/jfacmedbagdad.604758]
14. AL-Hadithi HS, Al-Derzi AR. The Pro-inflammatory IL6 and serum glucose in Polycystic Ovary Syndrome. J Fac Med Baghdad. 2013;55(2):149-51. [DOI:10.32007/jfacmedbagdad.552644]
15. Khodavirdilou R, Pournaghi M, Rastgar Rezaei Y, Hajizadeh K, Khodavirdilou L, Javid F, et al. Does Anti-Müllerian hormone vary during a menstrual cycle? A systematic review and meta-analysis. J Ovarian Res. 2022;15(1):78. [DOI:10.1186/s13048-022-01006-z] [PMID] []
16. Singh S, Firdaus A, Chaudhary R, Dhama V. Role of anti-mullerian hormone as a diagnostic tool for polycystic ovary syndrome. Int J Reprod Contraception, Obstet Gynecol. 2020;9(9):3730-7. [DOI:10.18203/2320-1770.ijrcog20203847]
17. Barbotin AL, Mimouni NEH, Kuchcinski G, Lopes R, Viard R, Rasika S, et al. Hypothalamic neuroglial plasticity is regulated by anti-Müllerian hormone and disrupted in polycystic ovary syndrome. EBioMedicine. 2023;90:104535. [DOI:10.1016/j.ebiom.2023.104535] [PMID] []
18. Yesiladali M, Yazici MGK, Attar E, Kelestimur F. Differentiating polycystic ovary syndrome from adrenal disorders. Diagnostics. 2022;12(9):2045. [DOI:10.3390/diagnostics12092045] [PMID] []
19. Santhiya R, Habeebullah S, Ghose S. Correlation of phenotypes of polycystic ovarian syndrome with anti-Müllerian hormone levels. Sahel Med J. 2021;24(1):15-21. [DOI:10.4103/smj.smj_50_20]
20. Mitra S, Saharia GK, Jena SK. Cardio-metabolic risk in Rotterdam clinical phenotypes of PCOS. Ann Endocrinol (Paris). 2024 Feb;85(1):44-47. [DOI:10.1016/j.ando.2023.06.001] [PMID]
21. Vaggopoulos V, Trakakis E, Panagopoulos P, Basios G, Salloum I, Christodoulaki C, Chrelias C. The prevalence of phenotypic subgroups in Greek women with polycystic ovarian syndrome. Clin Exp Obstet Gynecol. 2013;40(2):253-6.
22. Mehra T, Sharma S, Zahra T, Jangir S, Gupta B. Correlation of Body Mass Index with Anthropometric and Biochemical Parameters Among Polycystic Ovary Syndrome Phenotypes. Indian J Clin Biochem. 2023;38(2):231-241. [DOI:10.1007/s12291-022-01042-y] [PMID] []
23. Amini P, Omani-Samani R, Hosseini R, Ahmadi J, Maroufizadeh S. A cross-sectional comparison of clinical and endocrine parameters among phenotypes of polycystic ovarian syndrome in iranian population. Middle East Fertil Soc J. 2018;23(4):425-30. [DOI:10.1016/j.mefs.2018.07.005]
24. Fraissinet A, Robin G, Pigny P, Lefebvre T, Catteau-Jonard S, Dewailly D. Use of the serum anti-Müllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome. Hum Reprod. 2017;32(8):1716-1722. [DOI:10.1093/humrep/dex239] [PMID]
25. Sachdeva G, Gainder S, Suri V, Sachdeva N, Chopra S. Comparison of the Different PCOS Phenotypes Based on Clinical Metabolic, and Hormonal Profile, and their Response to Clomiphene. Indian J Endocrinol Metab. 2019;23(3):326-331. [DOI:10.4103/ijem.IJEM_30_19] [PMID] []
26. Głuszak O, Stopińska-Głuszak U, Glinicki P, Kapuścińska R, Snochowska H, Zgliczyński W, Dębski R. Phenotype and metabolic disorders in polycystic ovary syndrome. ISRN Endocrinol. 2012;2012:569862. [DOI:10.5402/2012/569862] [PMID] []
27. Gürsu T, Eraslan A, Angun B. Comparison of body mass index, anti-müllerian hormone and insulin resistance parameters among different phenotypes of polycystic ovary syndrome. Gynecol Obstet Clin Med. 2022;2(4):164-70. [DOI:10.1016/j.gocm.2022.10.002]
28. Wiweko B, Indra I, Susanto C, Natadisastra M, Hestiantoro A. The correlation between serum AMH and HOMA-IR among PCOS phenotypes. BMC Res Notes. 2018;11(1):114. [DOI:10.1186/s13104-018-3207-y] [PMID] []
29. Jamil AS, Alalaf SK, Al-Tawil NG, Al-Shawaf T. Comparison of clinical and hormonal characteristics among four phenotypes of polycystic ovary syndrome based on the Rotterdam criteria. Arch Gynecol Obstet. 2016;293(2):447-56. [DOI:10.1007/s00404-015-3889-5] [PMID]
30. Zawadski Jk, Dunaif A. Diagnostic Criteria for Polycystic Ovary Syndrome: Towards aRational Approach. Dunif A, Givens JR, Haseltine F, Eds., Polycystic Ovary Syndrome, Blakwell Scientific, Boston. 1992:377-84.
31. Caglar GS, Kahyaoglu I, Pabuccu R, Demirtas S, Seker R. Anti-Mullerian hormone and insulin resistance in classic phenotype lean PCOS. Arch Gynecol Obstet. 2013;288(4):905-10. [DOI:10.1007/s00404-013-2833-9] [PMID]
32. Önal M, ÖZTÜRK HÇ. Anti-Mullerian hormone and HOMA-IR in different phenotypes of polycystic ovary syndrome on insulin resistance. Anatol Curr Med J. 2023;5(4):376-82. [DOI:10.38053/acmj.1323489]
33. Ozay AC, Ozay OE, Gulekli B. Comparison of anti-müllerian hormone (aMh) and hormonal assays for Phenotypic Classification of Polycystic ovary Syndrome. Ginekol Pol. 2020;91(11):661-7. [DOI:10.5603/GP.a2020.0122] [PMID]
34. Pérez-López FR, Ornat L, López-Baena MT, Santabárbara J, Savirón-Cornudella R, Pérez-Roncero GR. Circulating kisspeptin and anti- müllerian hormone levels, and insulin resistance in women with polycystic ovary syndrome: A systematic review, meta-analysis, and meta-regression. Eur J Obstet Gynecol Reprod Biol. 2021;260:85-98. [DOI:10.1016/j.ejogrb.2021.03.007] [PMID]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
